See the DrugPatentWatch profile for vitrakvi
Does Medicare cover Vitrakvi (larotrectinib)?
Medicare coverage for a cancer drug like Vitrakvi (larotrectinib) depends on your Medicare type and whether the plan covers the drug under its prescription benefit. Medicare generally does not “cover” a specific drug in the abstract; coverage is usually determined by the Part D plan (or Part B, if the drug is given in a setting covered under Part B).
If you have Medicare Part D, will it cover Vitrakvi?
Most oral cancer medicines like Vitrakvi are billed through Medicare Part D (the prescription drug benefit), so coverage typically comes down to:
- Whether Vitrakvi is on your plan’s drug formulary
- Prior authorization requirements (common for cancer drugs)
- Step therapy rules (sometimes)
- Your cost-sharing (copays/coinsurance)
If you tell your Part D plan name (or whether you have Original Medicare vs a Medicare Advantage plan), coverage can be checked more precisely through your plan’s formulary.
If you’re on Medicare Advantage, can coverage differ?
Yes. Medicare Advantage plans (Part C) often have their own formularies and coverage rules. Even if both plans are Medicare-approved, they may differ on:
- Which tier Vitrakvi is placed on
- Prior authorization criteria
- Whether it’s covered only for certain diagnoses or line of therapy
What if Vitrakvi is given in a doctor’s office?
Vitrakvi is an oral medication, so it is usually handled under Part D. If a clinician administers a drug under a medical benefit in some cases, coverage rules can shift toward Part B, but that is not the typical billing path for Vitrakvi tablets/capsules.
How can you confirm coverage quickly?
To find out if your plan covers Vitrakvi, the fastest path is to ask your plan for:
- “Formulary status for Vitrakvi (larotrectinib)”
- “Any prior authorization or step therapy requirements”
- “Your expected copay/coinsurance”
If you share your state and the name of your plan, I can help you draft exactly what to ask.
Where Vitrakvi stands in patent/coverage research (drug info)
For background on Vitrakvi’s manufacturer and intellectual-property status, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/